FrancophonIA/ELRC3.0 huggingface dataset:
English: Oslif Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Slovenian: Zdravilo Oslif Breezhaler se uporablja za vzdrževanje odprtih dihalnih poti pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
English: The European Medicines Agency concluded that Oslif Breezhaler was shown to be effective at improving the lung function in COPD.
Slovenian: Evropska agencija za zdravila je zaključila, da je zdravilo Oslif Breezhaler dokazano učinkovito pri izboljševanju delovanja pljuč pri KOPB.
English: The active substance in Oslif Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist.
Slovenian: Zdravilna učinkovina v zdravilu Oslif Breezhaler, indakaterol, je agonist adrenergičnih receptorjev beta2.
English: For practical information about using Oslif Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Oslif Breezhaler naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: For the full list of all side effects and restrictions with Oslif Breezhaler, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Oslif Breezhaler glejte navodilo za uporabo.
English: When Oslif Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them.
Slovenian: Ko bolnik vdihne zdravilo Oslif Breezhaler, indakaterol doseže receptorje v dihalnih poteh in jih aktivira.
English: Other information about Oslif Breezhaler
Slovenian: Druge informacije o zdravilu Oslif Breezhaler
English: Oslif Breezhaler indacaterol
Slovenian: Oslif Breezhaler indakaterol
English: What is Oslif Breezhaler and what is it used for?
Slovenian: Kaj je zdravilo Oslif Breezhaler in za kaj se uporablja?
English: What benefits of Oslif Breezhaler have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Oslif Breezhaler izkazalo v študijah?
English: What are the risks associated with Oslif Breezhaler?
Slovenian: Kakšna tveganja so povezana z zdravilom Oslif Breezhaler?
English: Oslif Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
Slovenian: Zdravilo Oslif Breezhaler je bilo pri izboljšanju delovanja pljuč bolnikov s KOPB učinkovitejše od placeba.
English: Why is Oslif Breezhaler approved?
Slovenian: Zakaj je bilo zdravilo Oslif Breezhaler odobreno?
English: It is not intended to provide practical advice on how to use Oslif Breezhaler.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: How is Oslif Breezhaler used?
Slovenian: Kako se zdravilo Oslif Breezhaler uporablja?
English: How does Oslif Breezhaler work?
Slovenian: Kako zdravilo Oslif Breezhaler deluje?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom21 November 2014
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: The full European Public Assessment Report for Ceprotin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ceprotin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: As the CHMP was evaluating the initial documentation provided by the company, it had not yet made any recommendations.
Slovenian: Ker je CHMP ocenjeval začetno dokumentacijo, ki jo je predložila družba, še ni podal nobenih priporočil.
English: There are no consequences on the use of Ceprotin in its authorised indication.
Slovenian: Umik nima nobenih posledic za uporabo zdravila Ceprotin pri odobreni indikaciji.
English: Results from a retrospective study based on medical records of 94 children with congenital or acquired protein C deficiency were also provided.
Slovenian: Prav tako je predložil rezultate retrospektivne študije, ki je temeljila na zdravstvenih kartotekah 94 otrok s prirojenim ali pridobljenim pomanjkanjem proteina C.
English: The company informed the CHMP that there are no consequences for patients in clinical trials or compassionate use programmes.
Slovenian: Družba je odbor CHMP obvestila, da zavrnitev nima nobenih posledic za bolnike v kliničnih preskušanjih ali programih sočutne uporabe.
English: The application was withdrawn while CHMP was still evaluating the initial documentation provided by the company.
Slovenian: Vlogo so umaknili, medtem ko je odbor CHMP še vedno ocenjeval začetno dokumentacijo, ki jo je predložila družba.
English: On 22 October 2014, Baxter AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Ceprotin to treat acquired protein C deficiency.
Slovenian: Predlagatelj, družba Baxter AG, je dne 22. oktobra 2014 uradno obvestil Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo za zdravilo Ceprotin za zdravljenje pridobljenega pomanjkanja proteina C.
English: Ceprotin contains the active substance human protein C. It has been authorised in the EU since July
Slovenian: Zdravilo Ceprotin vsebuje zdravilno učinkovino humani protein C. V EU je odobreno od julija 2001.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it withdrew the application because in its preliminary assessment the CHMP was requesting additional clinical data to support the claim that Ceprotin is also effective in patients with acquired protein C deficiency.
Slovenian: Družba je v dopisu, s katerim Agencijo obvešča o umiku vloge, navedla, da je vlogo umaknila zato, ker je odbor CHMP v predhodni oceni zahteval dodatne klinične podatke, ki bi podprli trditev, da je zdravilo Ceprotin učinkovito tudi pri bolnikih s pridobljenim pomanjkanjem proteina C.
English: The applicant presented data from 2 main studies involving a total of 52 children with protein C deficiency due to severe infection, where Ceprotin was compared with placebo (a dummy treatment).
Slovenian: Predlagatelj je predložil podatke iz dveh glavnih študij, v katerih je sodelovalo skupno 52 otrok s pomanjkanjem proteina C zaradi hude okužbe in v katerih so zdravilo Ceprotin primerjali s placebom (zdravilom brez zdravilne učinkovine).
English: Ceprotin contains human protein C, extracted and purified from human plasma (the liquid part of the blood).
Slovenian: Zdravilo Ceprotin vsebuje humani protein C, ki je bil pridobljen in prečiščen iz človeške plazme (tekočega dela krvi).
English: What is Ceprotin?
Slovenian: Kaj je zdravilo Ceprotin?
English: What was Ceprotin expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Ceprotin uporabljalo?
English: In the body, protein C controls the generation of thrombin, one of the proteins involved in blood clotting.
Slovenian: Protein C v telesu nadzoruje nastajanje trombina, tj. ene od beljakovin, ki sodelujejo pri strjevanju krvi.
English: Protein C slows down the production of thrombin, and therefore slows down clotting.
Slovenian: Protein C upočasni nastajanje trombina in tako upočasni strjevanje krvi.
English: An injection of Ceprotin produces an immediate but temporary increase in levels of protein C, controlling clotting problems in protein C-deficient patients.
Slovenian: Injekcija zdravila Ceprotin takoj, vendar le za kratek čas zviša ravni proteina C, s čimer pomaga nadzorovati težave s strjevanjem krvi pri bolnikih s pomanjkanjem proteina C.
English: What is happening with Ceprotin for the treatment of patients with severe congenital protein C deficiency?
Slovenian: Kakšne so posledice za zdravilo Ceprotin, indicirano za zdravljenje hudega prirojenega pomanjkanja proteina C?
English: How is Ceprotin expected to work?
Slovenian: Kako naj bi zdravilo Ceprotin delovalo?
English: ‘Acquired' means that the disease is not inherited but develops during the patient's life and may occur for different reasons such as severe infection, liver disease or vitamin K deficiency.
Slovenian: Zdravilo Ceprotin naj bi se uporabljalo tudi pri bolnikih s „pridobljenim“ pomanjkanjem proteina C. „Pridobljeno“ pomeni, da bolezen ni dedna, ampak se pri bolniku razvije kasneje v življenju in se lahko pojavi zaradi različnih razlogov, kot so huda okužba, bolezen jeter ali pomanjkanje vitamina K.
English: Ceprotin is a medicine that is used to treat patients with severe congenital (hereditary) protein C deficiency and for the short-term prevention of blood clotting in patients with severe congenital protein C deficiency.
Slovenian: Ceprotin je zdravilo, ki se uporablja za zdravljenje bolnikov s hudim prirojenim (dednim) pomanjkanjem proteina C in za kratkotrajno preprečevanje strjevanja krvi pri bolnikih s hudim prirojenim pomanjkanjem proteina C. Podrobne informacije o odobreni uporabi zdravila Ceprotin v Evropski uniji (EU) so na voljo tukaj.
English: Pack size syringes (multipack)
Slovenian: 6 (3 x 2) napolnjenih injekcijskih peresnikov (skupno pakiranje)
English: 1 pre-filled pen pens (multipack)
Slovenian: 1 napolnjen injekcijski peresnik
English: EU-Number
Slovenian: Številka EU
English: Invented name Strength Pharmaceutical Form Route of administration Packaging Content (concentration) Package size
Slovenian: zaščiteno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
English: Your body's response to Repaglinide Accord may change if you take other medicines, especially these:
Slovenian: Odziv na zdravilo Repaglinide Accord se lahko spremeni, če jemljete še druga zdravila, še posebej:
English: This depolarises the β-cell and leads to an opening of the calcium channels.
Slovenian: To depolarizira celico  in povzroči odprtje kalcijevih kanalov.
English: 30 tablets 90 tablets 120 tablets 180 tablets 270 tablets
Slovenian: 30 tablet 90 tablet 120 tablet 180 tablet 270 tablet
English: • If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even death.
Slovenian: • Dolgotrajna nezdravljena huda hipoglikemija lahko povzroči (prehodno ali trajno) okvaro možganov in celo smrt.
English: 100 tablets in a HDPE bottle.
Slovenian: 100 tablet v HDPE steklenici.
English: Repaglinide Accord may not be suitable for you.
Slovenian: Zdravljenje z zdravilom Repaglinide Accord pri vas morda ni primerno.
English: Date of latest renewal: 19th September 2016
Slovenian: Datum prve odobritve: 22. december2011 Datum zadnjega podaljšanja: 19. september 2016
English: • If you take other medicines or suffer from liver or kidney problems (see other sections of 2.
Slovenian: • če uporabljate druga zdravila ali imate težave z jetri ali ledvicami (glejte ostale dele poglavja
English: Immune system disorders Allergic reactions*
Slovenian: Bolezni imunskega sistema alergijske reakcije*
English: Repaglinide pharmacokinetics are characterised by a mean absolute bioavailability of 63% (CV 11%).
Slovenian: Za farmakokinetiko repaglinida je značilna 63 % povprečna absolutna biološka uporabnost (CV 11 %).
English: This leaflet was last revised in.
Slovenian: Navodilo je bilo nazadnje revidirano:
English: No clinical studies have been conducted in patients >75 years of age.
Slovenian: Klinične študije pri bolnikih, starejših od 75 let, niso bile izvedene.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Slovenian: Podrobne informacije o tem zdravilu so dosegljive na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
English: The amount of Repaglinide Accord, food or exercise may need to be adjusted.
Slovenian: Morda bo treba prilagoditi odmerek zdravila Repaglinide Accord, količino zaužite hrane ali stopnjo telesne dejavnosti.
English: What Repaglinide Accord is and what it is used for What you need to know before you take Repaglinide Accord How to take Repaglinide Accord Possible side effects
Slovenian: Kaj je zdravilo Repaglinide Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Repaglinide Accord Kako jemati zdravilo Repaglinide Accord Možni neželeni učinki
English: • If you are allergic to repaglinide or any of the other ingredients in this medicine (listed in section
Slovenian: • ste alergični na repaglinid ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
English: What Repaglinide Accord is and what it is used for
Slovenian: Kaj je zdravilo Repaglinide Accord in za kaj ga uporabljamo
English: Do not take more Repaglinide Accord than your doctor has recommended.
Slovenian: Ne jemljite večjega odmerka zdravila Repaglinide Accord, kot vam ga je predpisal zdravnik.
English: What you need to know before you take Repaglinide Accord).
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Repaglinide Accord).
English: • Oral contraceptives (birth control pills)
Slovenian: • peroralne kontraceptive (tablete za nadzorovanje rojstev),
English: 4.7 Effects on ability to drive and use machines Repaglinide Accord has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.
Slovenian: Zdravilo Repaglinide Accord nima neposrednega vpliva na sposobnost vožnje in upravljanja s stroji, vendar pa lahko povzroči hipoglikemijo.
English: Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces.
Slovenian: Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka (pankreas) ne tvori dovolj insulina, da bi uravnal koncentracijo sladkorja v krvi ali pa se telo ne odziva normalno na insulin, ki ga sam proizvaja.
English: • If you have an infection or a fever
Slovenian: • če imate okužbo ali zvišano telesno temperaturo,
English: • Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1.
Slovenian: • Preobčutljivost za repaglinid ali katero koli pomožno snov navedeno v poglavju 6.1.
English: The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 patients (see If you get a hypo in section 2).
Slovenian: Hipoglikemija je najpogostejši neželeni učinek, ki se lahko pojavi pri največ 1 od 10 bolnikov (glejte odstavek V primeru pojava hipe v poglavju 2).
English: North Harrow, Middx HA1 4HF United Kingdom
Slovenian: North Harrow, Middlesex HA1 4HF Velika Britanija
English: Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present.
Slovenian: Zaradi sočasne uporabe rifampicina in repaglinida lahko torej pride do potrebe po prilagajanju odmerka repaglinida, ki mora temeljiti na skrbnem nadziranju vrednosti glukoze v krvi, tako ob uvedbi zdravljenja z rifampicinom (akutna inhibicija), kot ob nadaljevanju (mešana inhibicija in indukcija) ter ukinitvi zdravljenja (samo indukcija) in še približno do dva tedna po ukinitvi rifampicina, ko indukcijski učinek rifampicina izzveni.
English: Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Slovenian: Pogostnost je opredeljena kot: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: The total maximum daily dose should not exceed 16 mg. Special populations
Slovenian: Skupni največji dnevni odmerek ne sme preseči 16 mg.
English: • Clarithromycin, trimethoprim, rifampicin (antibiotic medicines)
Slovenian: • klaritromicin, trimetoprim, rifampicin (antibiotiki),
English: Other medicines and Repaglinide Accord
Slovenian: Druga zdravila in zdravilo Repaglinide Accord
English: Repaglinide Accord has been shown to lower the blood sugar, which helps to prevent complications from your diabetes.
Slovenian: Zdravilo Repaglinide Accord dokazano znižuje vrednost krvnega sladkorja, kar pomaga preprečiti razvoj zapletov zaradi sladkorne bolezni.
English: Repaglinide Accord is not recommended in patients with moderate liver disease.
Slovenian: Uporaba zdravila Repaglinide Accord pri bolnikih z zmerno boleznijo jeter ni priporočljiva.
English: Marketing authorisation holder and manufacturer Marketing authorisation holder Accord Healthcare S.L.U.
Slovenian: Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom Accord Healthcare S.L.U.
English: If you take more Repaglinide Accord than you should
Slovenian: Če ste vzeli večji odmerek zdravila Repaglinide Accord, kot bi smeli
English: When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised continue Repaglinide Accord treatment.
Slovenian: Ko simptomi hipoglikemije izzvenijo ali se koncentracija krvnega sladkorja ustali, nadaljujte zdravljenje z zdravilom Repaglinide Accord.
English: Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10B X02
Slovenian: Farmakoterapevtska skupina: Zdravila za sladkorno bolezen, ostala zdravila za nižanje glukoze v krvi, razen insulinov, oznaka ATC: A10BX02.
English: The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketoconazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids.
Slovenian: Naslednje učinkovine lahko povečajo in/ali podaljšajo hipoglikemični učinek repaglinida: gemfibrozil, klaritromicin, itrakonazol, ketokonazol, trimetoprim, ciklosporin, deferasiroks, klopidogrel, drugi antidiabetiki, zaviralci monoaminooksidaz (zaviralci MAO), neselektivni zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (zaviralci ACE), salicilati, nesteroidna protivnetna zdravila, oktreotid, alkohol in anabolni steroidi.
English: You can take Repaglinide Accord with metformin, another medicine for diabetes, if your doctor prescribes it.
Slovenian: Zdravilo Repaglinide Accord lahko jemljete skupaj z metforminom, drugim zdravilom za zdravljenje sladkorne bolezni, če vam takšno zdravljenje predpiše zdravnik.
English: CONDITIONS OR RESTRICTIONS WITH REGARDS TO SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
English: Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
Slovenian: Uporaba repaglinida je indicirana pri odraslih s sladkorno boleznijo tipa 2 diabetesom mellitusom, pri katerih hiperglikemije ni več mogoče zadovoljivo obvladovati z dieto, zmanjšanjem telesne mase in s telesno dejavnostjo.
English: OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Slovenian: DRUGI POGOJI IN ZAHTEVE ZA DOVOLJENJE ZA PROMET Z ZDRAVILOM
English: Repaglinide closes ATP-dependent potassium channels in the β-cell membrane via a target protein different from other secretagogues.
Slovenian: Repaglinid v membrani celic  zapre od ATP-odvisne kalijeve kanale, in sicer prek tarčne beljakovine, ki pa ni ista kot pri ostalih sekretagogih.
English: Repaglinide Accord is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).
Slovenian: Zdravilna učinkovina zdravila Repaglinide Accord je repaglinid, ki trebušni slinavki pomaga, da tvori več insulina in tako znižuje vrednost krvnega sladkorja (glukoze).
English: Repaglinide Accord can also be given with metformin, another medicine for diabetes.
Slovenian: Zdravilo Repaglinide Accord se lahko uporablja tudi skupaj z metforminom, drugim zdravilom za zdravljenje sladkorne bolezni.
English: • If you exercise more than usual
Slovenian: • če jeste več kot ponavadi,
English: Do not use Repaglinide Accord after the expiry date which is stated on the carton bottle label and blister after “EXP”.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in foliji pretisnega omota poleg oznake »Upor.
English: Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide.
Slovenian: Bolnike je mogoče na repaglinid prevesti neposredno z drugih peroralnih antidiabetikov.
English: • The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to
Slovenian: • Zdravnik lahko odmerek zviša do 4 mg, ki ga vzemite tik pred ali do 30 minut pred glavnimi obroki.
English: Repaglinide Accord is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar.
Slovenian: Zdravilo Repaglinide Accord uporabljamo za obvladovanje sladkorne bolezni tipa 2 pri odraslih kot dodatek k dieti in telesni dejavnosti: zdravljenje je treba uvesti, če samo z dieto, telesno dejavnostjo in zmanjšanjem telesne mase vrednosti sladkorja v krvi ni mogoče nadzirati (ali znižati).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 December 2011
Slovenian: Datum prve odobritve: 22. december 2011 Datum zadnjega podaljšanja: 19. september 2016
English: Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.
Slovenian: Uporaba repaglinida je indicirana tudi v kombinaciji z metforminom pri odraslih s sladkorno boleznijo tipa 2 diabetesom mellitusom, pri katerih glikemija samo z metforminom ni zadovoljivo urejena.
English: If you take gemfibrozil (used to lower increased fat levels in the blood) you should not take Repaglinide Accord.
Slovenian: Če jemljete gemfibrozil (zdravilo za zdravljenje zvišane vrednosti maščob v krvi), zdravila Repaglinide Accord ne smete jemati.
English: Allergy is very rare (may affect up to 1 in 10,000 patients).
Slovenian: Alergija je zelo redka (lahko se pojavi pri največ 1 od 10.000 bolnikov).
English: Aluminium/aluminium blister in packs containing 30, 90, 120, 180 or 270 tablets.
Slovenian: Pretisni omot (aluminij/aluminij) v pakiranjih, ki vsebujejo 30, 90, 120, 180 ali 270 tablet.
English: Repaglinide Accord should be taken with caution.
Slovenian: V tem primeru morate zdravilo Repaglinide Accord uporabljati previdno.
English: Repaglinide is rapidly absorbed from the gastrointestinal tract, which leads to a rapid increase in the plasma concentration of the active substance.
Slovenian: Repaglinid se hitro absorbira iz prebavil, zato se koncentracija zdravilne učinkovine v plazmi hitro zveča.
English: No clinical studies have been conducted in patients with hepatic insufficiency.
Slovenian: Pri bolnikih z jetrno insuficienco klinične študije niso bile izvedene.
English: If you forget to take Repaglinide Accord
Slovenian: Če ste pozabili vzeti zdravilo Repaglinide Accord
English: If you stop taking Repaglinide Accord
Slovenian: Če prenehate jemati zdravilo Repaglinide Accord
English: How to store Repaglinide Accord Contents of the pack and other information
Slovenian: Shranjevanje zdravila Repaglinide Accord Vsebina pakiranja in dodatne informacije